Skip to content

A Clinical Trial for Hospitalized Patients With COVID-19 in Ceará: ResCOVID Study

SARS-CoV-2 Epidemiology Study at e Referenced Hospital in Fortaleza, Brazil: ResCOVID Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04649827
Acronym
ResCOVID
Enrollment
3000
Registered
2020-12-02
Start date
2020-04-02
Completion date
2021-12-30
Last updated
2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, Hospitalization, Public Health

Brief summary

This is a case series of patients with COVID-19 admitted to the northeast Brazil region, in a referenced hospital for COVID-19, during the 2020 COVID-19 pandemic. Data will be collected prospectively and retrospectively. The main objective is to describe the characteristics of critically ill patients with COVID-19 and their clinical outcomes, and to identify risk factors associated with survival, to guide the strategy to mitigate the epidemic, both within each hospital and ICU and in public health management.

Detailed description

The world's population has been recently dealing with a new infectious disease, SARS-CoV-2 epidemic, which was first reported in December 2019 in Wuhan, China. The virus transmission was rapidly spread around the globe and the World Health Organization declared it as a public health emergency and it has been reported that SARS-CoV-2 is related to high morbidity and mortality rates. The total number of infected patients has risen fastly and at the end of February 2020, the first case in Brazil was confirmed, suggesting that the SARS-CoV-2 is a pandemic situation. The clinical aspect of SARS-CoV-2 ranges from pneumonia to critically ill cases, including clinical treatment, mechanical ventilation, and SARS. The acute respiratory failure of critically ill patients with COVID-19 has different aspects, including hypoxemia of difficult treatment, associated in some cases with clotting disorders, changes in immunity and inflammatory phenomena that pose challenges for the management of these patients, whose mortality can be higher than expected. The Public Health School in Fortaleza, Ceara, Brazil, implemented an action plan that provides several actions against COVID-19, including a specialized hospital and crew to treat these patients. Knowing the characteristics of critically ill patients with COVID-19 and their clinical outcomes is extremely important to inform clinical decision-making and to guide the strategy to mitigate the epidemic, both within each hospital and ICU and in public health management.

Interventions

OTHERClinical Observation

This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.

Sponsors

Escola de Saúde Pública do Ceará
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Confirmed COVID-19

Exclusion criteria

* N/A

Design outcomes

Primary

MeasureTime frameDescription
ICU outcomeup to 60 daysthe proportion of patients who survive to ICU discharge

Secondary

MeasureTime frameDescription
Hospital outcomeup to 90 daysthe proportion of patients who survive to hospitalization
Mechanical ventilationup to 60 daysMechanical ventilation time
Hospital complicationsup to 90 dayspercentage of patients who developed complications during the hospitalization, both at ICU and during total hospitalization.

Countries

Brazil

Contacts

Primary ContactJadson A' Franco
cep@esp.ce.gov.br+55853101

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026